ArticleAlzheimer's research & therapy2026
Development and validation of a novel panel of CSF biomarkers for Alzheimer's disease.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUsing proximity extension proteomic arrays (PEA), we previously identified a nine-biomarker CSF protein panel reflecting different biological processes dysregulated in Alzheimer´s disease (AD) that discriminated AD from non-AD dementias (i.e., dementia with Lewy bodies (DLB) and Frontotemporal dementia (FTD)). We translated this AD-Differential diagnostic panel into immunoassays for large-scale analysis and validated its discriminative performance in an independent cohort.
methodIn-house or commercially available immunoassays for five out of nine proteins (THOP1, ENO2, DDC, MMP7, and ITGB2) were analytically validated on the Ella platform. To verify analytical performance, results in CSF samples (n = 206) were compared between custom-PEA and Ella immunoassays. Clinical validation was performed in patients from the Amsterdam Dementia Cohort, including controls (cognitively unimpaired; n = 55, mean age: 57 ± 4 years, 36% females), amyloid-positive patients with mild cognitive impairment (MCI-Aβ+; n = 39, mean age: 68 ± 4 years, 46% females), AD (n = 47, mean age 66 ± 5 years, 31% females), and a non-AD group including patients with DLB (n = 54, mean age 69 ± 5 years, 17% females) and FTD (n = 50, mean age 64 ± 7 years, 32% females).
resultsModerate to strong correlations between custom-PEA and Ella immunoassays were observed (Rho’s > 0.646). CSF proteins showed similar though weaker trends compared to custom-PEA results. THOP1 and ENO2 were dysregulated across different AD stages. ENO2 and ITGB2 were increased in AD compared with DLB and FTD, while DDC was specifically increased in DLB. THOP1, ITGB2, and ENO2 correlated strongly with CSF pTau181 and tTau while weak correlations with amyloid were observed. Our CSF panel (THOP1, ENO2, DDC, MMP7, ITGB2) discriminated AD from non-AD dementias with moderate accuracy (AUC = 0.73, 95%CI: 0.64–0.82).
conclusionWe developed immunoassays for novel AD biomarker candidates, which cover relevant biological processes (i.e., cellular remodeling, neuropeptide degradation, energy metabolic processes, the immune system, and neurotransmitter synthesis) underlying AD pathophysiology. CSF patterns were consistent with our discovery study, albeit diagnostic performance was somewhat lower than observed previously. This highlights the need to further evaluate this panel, which monitors a broader spectrum of biological processes, both in clinical practice and within clinical trial settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.